Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT00724906
Other study ID # ALSE-A-02a, ALSE-A-02b
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received July 28, 2008
Last updated February 2, 2010
Start date July 2010
Est. completion date July 2011

Study information

Verified date February 2010
Source Alseres Pharmaceuticals, Inc
Contact Susan Flint, MS, RAC, CCRA, CCRP
Phone 508-497-2360
Email sflint@talarisadvisors.com
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This will be two separate but identical studies: ALSE-A-02a, ALSE-A02b. Each study is designed to evaluate the diagnostic accuracy and safety of a single dose of 123I-ALTROPANE® in subjects with upper extremity tremor for less than three years. Currently, no radiopharmaceutical diagnostic imaging agent has been approved by the FDA in the U.S. for use in diagnosing Parkinson disease and related Parkinsonian syndromes. The diagnosis of Parkinsonian syndromes in the U.S. is based on clinical criteria only. The goal is to demonstrate that 123I-ALTROPANE® paired with SPECT imaging permits a more accurate early diagnosis of Parkinson disease than a clinical diagnosis by a general neurologist.


Description:

Each study is a prospective, multi-center, non-randomized, open-label, out patient clinical trial which will include up to 240 subjects per study. Subjects will be male and female, age 40-80 years, with approximately 20 sites per study.

Subjects will participate in 5 study visits over the course of the study period. The screening visit will include an assessment of eligibility. The second visit will be the collection of the community neurologist's diagnostic assessment. The third visit, during which all subjects receive a single intravenous (IV) injection of 123I-ALTROPANE® and single photon emission computed tomography (SPECT) imaging, will include appropriate safety assessments before and after dosing. The fourth visit, to occur 24 to 72 hours after SPECT imaging, will include follow up safety assessments as well as the first Movement Disorder Specialist's (MDS) evaluation. The fifth visit, to occur 6 months (±7 days) after SPECT imaging, will include follow-up safety assessments as well as the MDS reevaluation and truth standard diagnosis. The subject's participation in the study will be up to 7 months.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 240
Est. completion date July 2011
Est. primary completion date July 2011
Accepts healthy volunteers No
Gender Both
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

1. Subjects must provide written informed consent prior to the initiation of any study related procedures;

2. Age 40 to 80 years;

3. Subjects must have had upper extremity tremor for < 3 years duration.

Exclusion Criteria:

1. Any clinically significant acute or unstable physical or psychological illness based on medical history or physical examination at Visit 1, as determined by the PI;

2. Any unexpected clinically significant abnormal laboratory or electrocardiogram (ECG) results obtained at Visit 1 and as determined by the PI;

3. Any history or drug, narcotic, or alcohol abuse within 2 years before the date of informed consent, as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, Fourth Edition, revised DSM-IVR, American Psychiatric Association, 1994;

4. Positive drug screen for opiates, cocaine or amphetamines at Visit 1;

5. Positive pregnancy test at Visit 1 and/or Visit 3;

6. Participation in an investigational drug or device clinical trial within 30 days prior to the date of informed consent;

7. Previous participation in any 123I-ALTROPANE® trial;

8. Any exposure to radiopharmaceuticals within 30 days prior to the date of informed consent;

9. Breast-feeding;

10. Inability to lie supine for 1 hour;

11. Any thyroid disease other than treated hypothyroidism;

12. Known sensitivity or allergy to iodine or iodine containing products;

13. Treatment within the 4 weeks before the date of the informed consent with buproprion, methylphenidate or amphetamine;

14. Any treatment with anti-Parkinson's drugs within 4 weeks before the date of informed consent.

Subject eligibility based on exclusion criteria 1, 2, 3, 4, and 20 will be confirmed at Visit 3 prior to dosing.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Drug:
123 I - ALTROPANE®
8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.

Locations

Country Name City State
United States Alseres Pharmaceuticals, Inc Hopkinton Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Alseres Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the diagnostic accuracy of a single dose of 123 I-ALTROPANE® as an imaging agent to aid in the diagnosis of Parkinsonian syndromes (PS) in subjects with upper extremity tremor for less than 2 years. 7 months No
Secondary To evaluate the safety of 123 I-ALTROPANE® in subjects with upper extremity tremor for less than 2 years. 7 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06193278 - Individual Neuromodulation for PDS N/A
Completed NCT00382967 - A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Phase 4
Recruiting NCT06161636 - Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease
Recruiting NCT02114242 - Biomarkers in Parkinsonian Syndromes